Exercise for the Enhancement of Cardiovascular Health in Black Men with Localized or Metastatic Prostate Cancer Undergoing Androgen Deprivation, POWER Trial

Inclusion Criteria

• Over 18 years old; children under the age of 18 will be excluded due to rarity of disease
• Histologically diagnosed of localized or metastatic prostate cancer (PCa)
• Have received ADT in the past for at least three months and or have been receiving ADT (i.e., luteinizing hormone-releasing hormone [LHRH] agonist/antagonist and/or androgen receptor [AR] agonist/antagonist) for at least one month with a plan to continue ADT for at least 4 months at the time of recruitment
• Self-identify as Black
• Medically cleared to participate in exercise by their referred physician or a certified clinical exercise physiologist
• Are without medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases
• Speak English and/or Spanish
• Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week
• Willing to travel to Dana Farber Cancer Institute (DFCI) for necessary data collection
• Ability to communicate and complete written forms in English and/or Spanish
• DAILY EXERCISE: Normal body temperature (=< 100 degrees Fahrenheit [F]); measured using a forehead thermometer bar
• DAILY EXERCISE: Normal resting heart rate (HR) (60-100 beats per minute [bpm]); absence of bradycardia (< 60 bpm) or tachycardia (> 100 bpm)
• DAILY EXERCISE: Normal resting blood pressure (=< 200/120 mmHg)

Exclusion Criteria

• Are not receiving ADT (i.e., LHRH agonist/antagonist and/or AR agonist/antagonist) or have not received at least three months of ADT in the past
• Pre-existing medical conditions such as uncontrolled cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise
• Are not English or Spanish speaking
• Patients receiving active treatment for a secondary cancer diagnosis (with the exception of basal cell carcinoma)
• Participate in more than 60 minutes of moderate or vigorous structured exercise/week
• Unable to travel to DFCI for necessary data collection
• May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator
• DAILY EXERCISE: Presence of fever (> 100 degrees F); measured using a forehead thermometer bar
• DAILY EXERCISE: Abnormal resting heart rate (< 60 bpm or > 100 bpm)
• DAILY EXERCISE: Severe arterial hypertension at rest (> 200/120 mmHg); measured using a sphygmomanometer (Omron Digital Blood Pressure Cuff)